Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
16.36
Nov 19 • 3:59 PM ET Dollar change+0.13 Percentage change(0.80%)
Aftermarket Close
16.36
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
64.68M
Enterprise Value
-12.48M
Income
-7.68M
Sales
36.84M
Book/sh
17.37
Cash/sh
19.52
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
26
IPO
Jul 30, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
1.76
P/B
0.94
P/C
0.84
P/FCF
-
EV/EBITDA
-
EV/Sales
-0.34
Quick Ratio
11.19
Current Ratio
11.19
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-0.91
EPS next Y
-3.84
EPS next Q
-1.11
EPS this Y
46.44%
EPS next Y
-124.04%
EPS next 5Y
-10.73%
EPS past 3/5Y
32.12% 14.99%
Sales past 3/5Y
- -
EPS Y/Y TTM
81.41%
Sales Y/Y TTM
216600.00%
EPS Q/Q
13.37%
Sales Q/Q
-
Insider Own
47.93%
Insider Trans
0.00%
Inst Own
31.01%
Inst Trans
10.12%
ROA
-8.62%
ROE
-10.95%
ROIC
-11.02%
Gross Margin
99.99%
Oper. Margin
-29.80%
Profit Margin
-20.84%
SMA20
-25.71%
SMA50
-38.88%
SMA200
-49.62%
Trades
Shs Outstand
4.01M
Shs Float
2.06M
52W High
44.00 -62.82%
52W Low
16.00 2.25%
Volatility
8.02% 6.45%
ATR (14)
1.45
RSI (14)
17.34
Beta
0.39
Rel Volume
0.52
Avg Volume
33.86K
Volume
17,645
Perf Week
-20.93%
Perf Month
-41.09%
Perf Quarter
-50.80%
Perf Half Y
-53.92%
Perf YTD
-59.09%
Perf Year
-49.26%
Perf 3Y
10.18%
Perf 5Y
-71.20%
Perf 10Y
-93.00%
Prev Close
16.23
Price
16.36
Change %
0.80%
Consensus
Strong Buy
Avg. Price Target
$59.57
Implied Upside
+264.1%
Analysts10incl. previous ratings
Rating Distribution9 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 30, 2026Initiated
RRodman & Renshaw
Buy$67+309.5%
Mar 12, 2026Initiated
EVR logoEEvercore ISI
Outperform$44+168.9%
Jan 23, 2026Initiated
RRoth Capital
Buy$58+254.5%
Jan 05, 2026Initiated
TD logoTTD Cowen
Buy$67+309.5%
Nov 19, 2025Initiated
BBTIG Research
Buy$40+144.5%
May 30, 2019Initiated
HH.C. Wainwright
Buy
Apr 10, 2018Downgrade
SF logoSStifel
Buy → Hold$12 → $1-93.9%
Mar 08, 2018Initiated
RROTH Capital
Buy$17+3.9%
Feb 08, 2018Initiated
NNorthland Capital
Outperform$28+71.1%
Sep 26, 2016Initiated
HH.C. Wainwright
Buy$13-20.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Samsara BioCapital, L.P.ShareholderNov 12 '26Proposed Sale21.4761,2871,315,832Nov 12 05:59 PM
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
CEOMr. Paul J. Sekhri
M.D.Dr. Michael Steven Tung M.B.A.
Chief Accounting OfficerMr. Barry K. Brown
Chief Scientific Officer & Executive VPDr. Carmen Valcarce Ph.D.
Executive VP & General CounselMs. Elizabeth M. Keiley